Yi XM, Cai HQ, Jiao Y. Programmed cell death receptor 1 inhibitor Pembrolizumab in the treatment of advanced gastric cancer. World J Gastrointest Surg 2025; 17(2): 100257 [DOI: 10.4240/wjgs.v17.i2.100257]
Corresponding Author of This Article
Yan Jiao, MD, PhD, Doctor, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun 130021, Jilin Province, China. lagelangri1@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Feb 27, 2025; 17(2): 100257 Published online Feb 27, 2025. doi: 10.4240/wjgs.v17.i2.100257
Programmed cell death receptor 1 inhibitor Pembrolizumab in the treatment of advanced gastric cancer
Xue-Mei Yi, Hong-Qiao Cai, Yan Jiao
Xue-Mei Yi, Department of Second Operation Room, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Hong-Qiao Cai, Yan Jiao, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Author contributions: Yi XM contributed to the discussion and design of the manuscript; Yi XM and Cai HQ contributed to the writing, and editing the manuscript, illustrations, and review of literature; Jiao Y designed the overall concept and outline of the manuscript; all of the authors read and approved the final version of the manuscript to be published.
Supported by Jilin Provincial Natural Science Foundation, No. YDZJ202401650ZYTS.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Jiao, MD, PhD, Doctor, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun 130021, Jilin Province, China. lagelangri1@126.com
Received: August 11, 2024 Revised: December 18, 2024 Accepted: December 25, 2024 Published online: February 27, 2025 Processing time: 163 Days and 20 Hours
Abstract
This editorial discusses Christodoulidis et al's article, which appeared in the most recent edition. The clinical trials have demonstrated the programmed cell death receptor 1 (PD-1) inhibitor Pembrolizumab involved combination therapy can improve the efficacy of advanced gastric cancer (AGC). Pembrolizumab combined with chemotherapy can enhance its sensitivity, and further eliminate tumor cells that develop resistance to chemotherapy. The combination of Pembrolizumab and Trastuzumab targeting human epidermal growth factor receptor 2 showed improved prognosis. The overall toxic effects of Pembrolizumab are significantly lower than traditional chemotherapy, and the safety is controllable. PD-1 inhibitor Pembrolizumab sheds a light on the treatment of AGC and brings new hope to the clinical practice.
Core Tip: In the past decade, programmed cell death receptor 1 (PD-1) inhibitors have shown significant anti-tumor effects and good safety in the treatment of various malignant tumors such as melanoma and non-small cell lung cancer. Multiple studies on advanced gastric cancer have shown that the combination therapy of PD-1 inhibitors can improve the efficacy. Pembrolizumab combined with chemotherapy or human epidermal growth factor receptor 2 targeting therapy have showed improved prognosis. In the future, it is important to explore the reasonable treatment sequence and dosage, to maximize the efficacy of combination therapy.
